Clinical Trial Update: An Open Label Dose Escalation Safety Study of Convection-Enhanced Delivery of IL13-PE38QQR in Patients With Progressive Pediatric Diffuse Infiltrating Brainstem Glioma and Supratentorial High-grade Glioma [Phase 1]

View source ↗

Summary

This is a terminated Phase 1 open-label study evaluating convection-enhanced delivery of IL-13-PE38QQR in pediatric diffuse infiltrating brainstem glioma and su…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Neoplasms
• Glioma

Drugs mentioned

• IL-13-PE38QQR (IL-13-PE38QQR)

Snippet

Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) | Conditions: Brain Neoplasm, Glioma | Phase 1 | Status: TERMINATED